My previous reasoning was that the data for interim was between p= .05 and p=.005. The DSMC and of course the FDA would have wanted to see p= .005 for a trial halt for efficacy due to the very broad confidence interval or power. The number of patients for the full trial would have been set up so p= .05 and the 390 patients would have a suitable confidence interval.